Psychedelic highlights | January 18 – 22

Shares :

5
(1)
Psychedelic highlights | January 18 – 22

Here is a summary of the news from the last week in the psychedelics market. The value of the psychedelics market is more than $100 billion according to Cannacord most recent report.

Psychedelic market value by company

Last week performance

COMPANYTICKERJAN 22WEEK %
Red Light HollandsTRIP$0.51+ 59 %
Psyched WellnessPSYC$0.37+ 29 %
Field TripFTRP$4.91+ 21 %
NuminusNUMI$1.60+ 20 %
MindMedMMED$4.62+ 17 %
CompassCMPS$48.32+ 13 %
Mind CureMCUR$0.74+ 7%
M2Bio SciencesWUHN$0.40+ 4 %
Revive TherapeuticsRVV$0.59– 1.5 %
Cybin Inc. CYBN$2.39– 4 %

Story of the week

1. What’s coming for M2Bio Sciences in 2021 ? [featured]

The CEO of M2Bio Sciences (Wuhan General Group), Jeff Robinson, provided an update on the company in an interview which has just been published.

For Jeff, 2021 will be an incredible year for M2Bio Sciences and will take the company to another level.

It is clear that with a valuation of only $19 Million, M2Bio Sciences is a godsend with everything to come for the company.

Read the full article HERE


2. MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA and LSD [news release]

MindMed announced today the start of the first ever clinical trial measuring and evaluating MDMA and LSD used in combination in the human body.

The trial will be conducted at the University Hospital Basel Liechti Lab, in Basel, Switzerland.

Read the full news HERE


3. Psyched Wellness Announces New OTCQB Ticker: PSYCF and Submits an Application to Register a Trademark for the Company’s Unique Extraction [news release]

Psyched Wellness  is pleased to announce that it has submitted an application with the United States Patent and Trademark Office (USPTO) to register the trademark “AME-1” in connection with the Company’s unique extraction.

And more, Psyched Wellness announce that FINRA accepted its proposed symbol change for the OTCQB market from the former DCNPF to PSYCF.

Read the full news HERE


4. Entheon Biomedical Partners with Divergence Neuro Technologies Inc. for Predictive Biomarker Platform Development [news release]

Entheon announced a partnership with Divergence Neuro Technologies Inc. (“Divergence”), a company focused on the research and development of a data-driven, cloud-based neuro platform based on electroencephalogram (“EEG“) analysis and machine learning, to research and develop N, N-Dimethyltryptamine (“DMT”) biomarkers (“Biomarkers”) and a predictive model of biomarker responses to drug dosage and delivery of DMT-based psychedelic therapeutic products (the “DMT Products”) targeted to treat a number of different addiction and substance use disorders (hereto referred to as the “DMT Biomarker Model”). 

Read the full news HERE


5. Lobe Sciences Announces Management Changes and New Director [news release]

Lobe Sciences is pleased to announce the appointment of Mr. Philip J. Young as Chief Executive Officer, Corporate Secretary and a director of the Company, effective January 15, 2021.

Mr. Young replaces Thomas Baird, who resigned as CEO as of the same date. 

Read the full news HERE


6. PharmaTher Signs Exclusive Worldwide License Agreement for Patented Ketamine Formulation Targeting Mental Health, Neurological and Pain Disorders [news release]

PharmaTher is pleased to announce that PharmaTher has entered into an Exclusive Worldwide License Agreement (the “Agreement”) with the National Health Research Institutes (“NHRI”) for the development and commercialization of a patented combination formulation of FDA-approved ketamine and betaine (“KETABET™”) as a potential next-generation ketamine treatment for mental health, neurological and pain disorders.

Read the full news HERE


Sign up for MORE news updates !


This article is written and published by The Cannabis Stock


Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best articles and news on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Cannabis Stock are engaged in the business of marketing and advertising companies

The Cannabis Stock and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.

Click on a star to rate this article !

Average rating 5 / 5. Vote count: 1

No votes so far! Be the first to rate this post.


Shares :